Literature DB >> 21547915

Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors.

Ole Helmer Sjo1, Marianne Berg, Marianne Arstad Merok, Matthias Kolberg, Aud Svindland, Ragnhild A Lothe, Arild Nesbakken.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of the study was to evaluate the incidence of peritoneal carcinomatosis (PC) in a prospectively recorded series of colon cancer patients from a defined cohort and to compare clinicopathological characteristics, survival, and TP53 mutation status in primary tumors from patients with and without PC.
METHODS: Clinical data from all colon cancer patients admitted in 1993-2006 were registered prospectively (n = 1,124). In a subset of PC patients, DNA was retrieved from tumor tissue and TP53 mutations analyzed and compared to the mutation status in a historical series.
RESULTS: In the prospective series 10% of female and 7% of male patients had PC (P = 0.05). The PC patients were younger than those without PC (median 4 years, P = 0.002). The incidence of PC was 10.3% and 6.2% (P = 0.03) in patients with primary tumors in the right and left colon, respectively. TP53 was mutated in 57% of the PC patients as compared to 41% in the series of patients without PC (P = 0.05).
CONCLUSIONS: The incidence of PC was higher in right-sided colon cancer and among women. PC patients were younger than non-PC patients, and PC was independently associated with TP53 mutation in the primary tumor.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547915     DOI: 10.1002/jso.21959

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer.

Authors:  Guanfang Ping; Wancheng Xiong; Lanfang Zhang; Yanru Li; Yusong Zhang; Yongli Zhao
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  Risk Factors for Synchronous Peritoneal Metastases in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yuanxin Zhang; Xiusen Qin; Rui Luo; Hui Wang; Huaiming Wang; Hongzhi Luo
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 3.  Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer.

Authors:  Paul H Sugarbaker
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 4.  Biomarker-guided therapy for colorectal cancer: strength in complexity.

Authors:  Anita Sveen; Scott Kopetz; Ragnhild A Lothe
Journal:  Nat Rev Clin Oncol       Date:  2019-07-09       Impact factor: 66.675

5.  How many diseases are colorectal cancer?

Authors:  A Greystoke; S A Mullamitha
Journal:  Gastroenterol Res Pract       Date:  2012-09-09       Impact factor: 2.260

6.  Overexpression of microRNA‑101 causes anti‑tumor effects by targeting CREB1 in colon cancer.

Authors:  Qinglin Yang; Weijie Yu; Xiaoli Han
Journal:  Mol Med Rep       Date:  2019-02-14       Impact factor: 2.952

7.  Metastatic Mucinous Adenocarcinoma of Gastrointestinal Origin: A Rare Presentation of Peritoneal Carcinomatosis in a Woman.

Authors:  Krista M Wong; Mohammad Haidous; Zain AlShanableh; Poornanand Palaparty; Keyvan Ravakhah
Journal:  Cureus       Date:  2022-02-23

8.  Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.

Authors:  Peihao Yin; Yan Wang; YanYan Qiu; LiLi Hou; Xuan Liu; Jianmin Qin; Yourong Duan; Peifeng Liu; Ming Qiu; Qi Li
Journal:  Int J Nanomedicine       Date:  2012-07-27

9.  Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation.

Authors:  Le-Gao Chen; Ying-Jie Xia; Ying Cui
Journal:  Oncol Rep       Date:  2017-05-24       Impact factor: 3.906

10.  FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.

Authors:  Yihong Chen; Ganlu Deng; Yaojie Fu; Ying Han; Cao Guo; Ling Yin; Changjing Cai; Hong Shen; Shaobin Wu; Shan Zeng
Journal:  Onco Targets Ther       Date:  2020-02-21       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.